Lilly hits the breaks on R&D due to COVID-19


  • 1585207563930
  • Brazil,Mexico,Colombia,Argentina,Chile,Ecuador ,Puerto Rico ,Costa Rica,Peru,Venezuela
  • Company
  • Pharma & Biotech

Eli Lilly this week announced it will delay most of its recruiting and planned clinical trials (CTs) worldwide to reduce stress on healthcare systems due to the current COVID-19 pandemic. A Phase III global study on mirikizumab against Crohn’s disease taking place in Argentina will be the only late-stage CT affected, while ongoing trials will continue so as to not disrupt patients’ treatments.

According to the company, the pandemic is not impacting its supply of medicines and will not affect its financial performance during 2020.

GBI analysis shows that Eli Lilly is currently sponsoring 781 CTs in Latin America, mostly in Mexico, Puerto Rico, Argentina, and Brazil with 219, 200, 154, and 131 studies respectively. Trials planned to begin this year in Latin America include the mirikizumab CT, as well as a dulaglutide Phase III study in diabetes and a Phase I/II trial evaluating nivolumab against non-small cell lung cancer (NSCLC). Enrolling CTs that face entering hiatus include 24 in Mexico, 20 in Argentina, 18 in Brazil, 17 in Puerto Rico, 4 in Colombia, and 3 in Chile.

Reference:

Related news
Eli Lilly this week announced it is temporarily calling a halt to new clinical trials (CTs) worldwide to reduce stress on healthcare systems amid the ongoing COVID-19 pandemic.
The Center for Drug Evaluation (CDE) indicates that multiple programmed death-1 (PD-1)/programmed death-ligand-1 (PD-L1) inhibitors already marketed in and outside of China have gained clinical trial approvals for new indications.
US major Eli Lilly & Co., Inc., published its Q4 2019 financials report, revealing full-year revenues growth of 4% year-on-year (YOY) to USD 22.32 billion.
Suzhou-based biotech Innovent Biologics (HKEX.01801) and US major Eli Lilly (NSDQ:LLY) revealed that the combination of Innovent’s anti-programmed death-1 (PD-1) inhibitor Tyvyt (sintilimab) with Lilly’s Alimta (pemetrexed disodium) chemotherapy plus platinum has achieved the primary endpoint in a Phase III clinical trial.
Denmark’s Novo Nordisk this week received registration approval from Colombia’s National Food and Drug Surveillance Institute (INVIMA) for its antidiabetic Ozempic (semaglutide), according to GBI analysis.
Recent news
The National Medical Products Administration (NMPA) last week revealed that Celgene’s Abraxane (paclitaxel, albumin bound) would lose its import clearance after agency inspectors uncovered manufacturing issues at the Fresenius Kabi plant responsible for manufacturing the drug. The news impacts Chinese biotech BeiGene Inc., which generated around USD 100 million with Abraxane in China as the drug's marketing agent under license from Celgene.
  • 1585666816337
  • China
Pfizer subsidiary Wyeth this week obtained a marketing approval from Brazil's National Health Surveillance Agency (ANVISA) for its iron replacement therapy Monofer (ferric derisomaltose), as GBI analysis shows.
Hugo Sigman, founder of of Argentina-based group Insud Pharma, last week commented on Argentina’s biopharmaceutical industry as the COVID-19 pandemic puts the health sector to test.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
GoBroad Healthcare Group broke ground on construction of a research hospital in Beijing’s Future Science Park this week.
Analytics Snapshot


Analytics Snapshot